Status:
UNKNOWN
Role of Prophylactic Postoperative Antibiotics in HoLEP
Lead Sponsor:
Baylor Research Institute
Collaborating Sponsors:
Albert Einstein Healthcare Network
Conditions:
Benign Prostatic Hyperplasia
Urinary Tract Infections
Eligibility:
MALE
40+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to investigate whether prescribing a 3-day course of antibiotics after Holmium laser enucleation of the prostate (HoLEP) reduces the risk of urinary tract infection. The f...
Detailed Description
Systemic antibiotic usage is the primary driver of antimicrobial resistance both in the index patient and the community. Limiting antibiotic use to indicated patients helps reduction of the risks of a...
Eligibility Criteria
Inclusion
- Men \> 40 years old with moderate to severe lower urinary tract symptoms due to benign prostatic hyperplasia (BPH).
- Patient with negative preoperative urine culture.
Exclusion
- Patients with history of recurrent urinary tract infection or uro-sepsis.
- Patient with preoperative infections
- Patient with indwelling urethral catheter
- Patient doing continuous intermitted catheterization (CIC)
Key Trial Info
Start Date :
March 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05274672
Start Date
March 1 2022
End Date
June 1 2023
Last Update
March 11 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Einstein Healthcare network
Philadelphia, Pennsylvania, United States, 19141
2
Baylor Scott and White
Temple, Texas, United States, 76508